# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATIONDECISION SUMMARYINSTRUMENT ONLY TEMPLATE

A. 510(k) Number: K072727   
B. Purpose for Submission: Special 510(k) for hardware and software modifications   
C. Manufacturer and Instrument Name: HemoSense, INC   
D. Type of Test or Tests Performed: Prothrombin Time Test   
E. System Descriptions: 1. Device Description:

The INRatio 2 PT Monitoring System consists of a monitor, disposable test strips, user guide, quick reference guide, training video/DVD, and testing supplies.

# 2. Principles of Operation:

The INRatio 2 PT Monitoring System performs a modified version of the one-stage prothrombin time test using a recombinant human thromboplastin reagent. The clot formed in the prothrombin time reaction is detected by a change in the electrical impedance of the sample during the coagulation process.

3. Modes of Operation: Manual mode.

4. Specimen Identification: Manual input

5. Specimen Sampling and Handling:

Capillary blood is added directly to the test strip

6. Calibration:

Factory calibration. The monitor performs self-checks at start-up and throughout the testing process.

7. Quality Control: On board bi-level controls

8. Software:

FDA has reviewed applicantâ€™s Hazard Analysis and Software Development processes for this line of product types:

Yes___X_ _ or No_

# F. Regulatory Information:

1. Regulation section:   
21 CFR 864.7750

2. Classification: Class II

3 Product code: GJS

4. Panel: 81 Hematology

# G. Intended Use:

1. Indication(s) for Use:

The INRatio 2 PT Monitoring System is used for the quantitative measurement of prothrombin time (PT) in fresh, capillary whole blood. The INRatio 2 PT Monitoring system is intended for use outside the body (in vitro diagnostic use) by people taking warfarin and other oral anticoagulant (blood thinning) therapy who need to monitor the clotting time of their blood. The INRatio 2 PT Monitoring system is not intended to be used for screening purposes.

# H. Substantial Equivalence Information:

1. Predicate Device Name(s) and 510(k) numbers: HemoSense INRatio (K020679)

2. Comparison with Predicate Device:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Quantitative measurementof prothrombin time infresh capillary wholeblood</td><td rowspan=1 colspan=1>same</td></tr><tr><td rowspan=1 colspan=1>Sample Volume</td><td rowspan=1 colspan=1>15 ul</td><td rowspan=1 colspan=1>same</td></tr><tr><td rowspan=1 colspan=1>QC</td><td rowspan=1 colspan=1>Onboard bi-level controls</td><td rowspan=1 colspan=1>same</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Memory</td><td rowspan=1 colspan=1>120 tests</td><td rowspan=1 colspan=1>60 tests</td></tr><tr><td rowspan=1 colspan=1>Software- Access</td><td rowspan=1 colspan=1>From various buttons</td><td rowspan=1 colspan=1>Only from Menu button</td></tr><tr><td rowspan=1 colspan=1>Software - Printingcapability from memory</td><td rowspan=1 colspan=1>No capability</td><td rowspan=1 colspan=1>Able to</td></tr><tr><td rowspan=1 colspan=1>Display Screen</td><td rowspan=1 colspan=1>LCD, FSTN, 44mmH x58 mmW</td><td rowspan=1 colspan=1>LCD, 128 x 64 matrix</td></tr><tr><td rowspan=1 colspan=1>Device size</td><td rowspan=1 colspan=1>5.9&#x27;H x 2.9&quot; W x 1.8&quot; D</td><td rowspan=1 colspan=1>6.2&quot;H x 3&quot; W x 2.25&quot; D</td></tr></table>

# I. Special Control/Guidance Document Referenced (if applicable):

# J. Performance Characteristics:

1. Analytical Performance: a. Accuracy:

b. Precision/Reproducibility:

c. Linearity:

d. Carryover:

e. Interfering Substances:

2. Other Supportive Instrument Performance Data Not Covered Above:

As required for a Special 510(k), the Sponsor has provided a risk analysis as well as a Declaration of Conformity with Design Controls indicating that development activities were conducted under appropriate design controls procedures, and the overall product specifications were met.

# K. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# L. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.